{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:50:56Z","timestamp":1778885456037,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,10,14]],"date-time":"2014-10-14T00:00:00Z","timestamp":1413244800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s40618-014-0185-3","type":"journal-article","created":{"date-parts":[[2014,10,13]],"date-time":"2014-10-13T08:19:12Z","timestamp":1413188352000},"page":"361-366","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Epicardial fat, body mass index, and triglyceride are independent contributors of serum fibroblast growth factor 21 level in obese premenopausal women"],"prefix":"10.1007","volume":"38","author":[{"given":"Z. I.","family":"Akyildiz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Polat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. S.","family":"Yurekli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. U.","family":"Kocabas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Tuluce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Y.","family":"Tuluce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Kocabas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Bozkaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Yuksel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Nazli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,10,14]]},"reference":[{"key":"185_CR1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/cen.12134","volume":"80","author":"Y Lee","year":"2014","unstructured":"Lee Y, Lim S, Hong ES et al (2014) Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status. Clin Endocrinol (Oxf) 80:57\u201364","journal-title":"Clin Endocrinol (Oxf)"},{"key":"185_CR2","first-page":"97","volume":"4","author":"SH Choi","year":"2013","unstructured":"Choi SH, Hong ES, Lim S (2013) Clinical implications of adipocytokines and newly emerging metabolic factors with relation to insulin resistance and cardiovascular health. Front Endocrinol (Lausanne) 4:97","journal-title":"Front Endocrinol (Lausanne)"},{"key":"185_CR3","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1365-2362.2010.02338.x","volume":"40","author":"Y Yilmaz","year":"2010","unstructured":"Yilmaz Y, Eren F, Yonal O et al (2010) Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest 40:887\u2013892","journal-title":"Eur J Clin Invest"},{"key":"185_CR4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1055\/s-2007-985148","volume":"116","author":"WW Chen","year":"2008","unstructured":"Chen WW, Li L, Yang GY et al (2008) Circulating FGF-21 levels in normal subjects and in newly diagnosed patients with Type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 116:65\u201368","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"185_CR5","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.metabol.2010.02.016","volume":"60","author":"K Mai","year":"2011","unstructured":"Mai K, Schwarz F, Bobbert T et al (2011) Relation between fibroblast growth factor-21, adiposity, metabolism, and weight reduction. Metabolism 60:306\u2013311","journal-title":"Metabolism"},{"key":"185_CR6","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2337\/db07-1476","volume":"57","author":"X Zhang","year":"2008","unstructured":"Zhang X, Yeung DC, Karpisek M et al (2008) Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57:1246\u20131253","journal-title":"Diabetes"},{"key":"185_CR7","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.metabol.2010.03.018","volume":"59","author":"SH Han","year":"2010","unstructured":"Han SH, Choi SH, Cho BJ et al (2010) Serum fibroblast growth factor-21 concentration is associated with residual renal function and insulin resistance in end-stage renal disease patients receiving long-term peritoneal dialysis. Metabolism 59:1656\u20131662","journal-title":"Metabolism"},{"key":"185_CR8","doi-asserted-by":"crossref","first-page":"e15534","DOI":"10.1371\/journal.pone.0015534","volume":"5","author":"Z Lin","year":"2010","unstructured":"Lin Z, Wu Z, Yin X et al (2010) Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One 5:e15534","journal-title":"PLoS One"},{"key":"185_CR9","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/cen.12095","volume":"78","author":"YC Woo","year":"2013","unstructured":"Woo YC, Xu A, Wang Y, Lam KS (2013) Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin Endocrinol (Oxf) 78:489\u2013496","journal-title":"Clin Endocrinol (Oxf)"},{"key":"185_CR10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1210\/en.2010-1262","volume":"153","author":"C Hale","year":"2012","unstructured":"Hale C, Chen MM, Stanislaus S et al (2012) Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance. Endocrinology 153:69\u201380","journal-title":"Endocrinology"},{"key":"185_CR11","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1210\/en.2008-0816","volume":"149","author":"T Coskun","year":"2008","unstructured":"Coskun T, Bina HA, Schneider MA et al (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149:6018\u20136027","journal-title":"Endocrinology"},{"key":"185_CR12","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1210\/en.2006-1168","volume":"148","author":"A Kharitonenkov","year":"2007","unstructured":"Kharitonenkov A, Wroblewski VJ, Koester A et al (2007) The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148:774\u2013781","journal-title":"Endocrinology"},{"key":"185_CR13","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2337\/db08-0392","volume":"58","author":"J Xu","year":"2009","unstructured":"Xu J, Lloyd DJ, Hale C et al (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58:250\u2013259","journal-title":"Diabetes"},{"key":"185_CR14","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1172\/JCI67353","volume":"3","author":"B Emanuelli","year":"2014","unstructured":"Emanuelli B, Vienberg SG, Smyth G et al (2014) Interplay between FGF21 and insulin action in the liver regulates metabolism. J Clin Invest 3:515\u2013527","journal-title":"J Clin Invest"},{"key":"185_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2840-5-1","volume":"5","author":"AR Baker","year":"2006","unstructured":"Baker AR, Silva NF, Quinn DW et al (2006) Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc Diabetol 5:1","journal-title":"Cardiovasc Diabetol"},{"key":"185_CR16","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/ncpcardio0319","volume":"2","author":"G Iacobellis","year":"2005","unstructured":"Iacobellis G, Corradi D, Sharma AM (2005) Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nat Clin Pract Cardiovasc Med 2:536\u2013543","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"185_CR17","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.echo.2009.10.013","volume":"22","author":"G Iacobellis","year":"2009","unstructured":"Iacobellis G, Willens HJ (2009) Echocardiographic epicardial fat: a review of research and clinical applications. J Am Soc Echocardiogr 22:1311\u20131319","journal-title":"J Am Soc Echocardiogr"},{"key":"185_CR18","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","volume":"24","author":"RM Conroy","year":"2003","unstructured":"Conroy RM, Pyorala K, Fitzgerald AP et al (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24:987\u20131003","journal-title":"Eur Heart J"},{"key":"185_CR19","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"J Perk","year":"2012","unstructured":"Perk J, De Backer G, Gohlke H et al (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 33:1635\u20131701","journal-title":"Eur Heart J"},{"key":"185_CR20","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.2337\/db10-0193","volume":"59","author":"FM Fisher","year":"2010","unstructured":"Fisher FM, Chui PC, Antonellis PJ et al (2010) Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 59:2781\u20132789","journal-title":"Diabetes"},{"key":"185_CR21","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3109\/07435800.2011.558550","volume":"36","author":"X Cheng","year":"2011","unstructured":"Cheng X, Zhu B, Jiang F, Fan H (2011) Serum FGF-21 levels in type 2 diabetic patients. Endocr Res 36:142\u2013148","journal-title":"Endocr Res"},{"key":"185_CR22","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1210\/jc.2008-2331","volume":"94","author":"H Li","year":"2009","unstructured":"Li H, Bao Y, Xu A et al (2009) Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab 94:2151\u20132156","journal-title":"J Clin Endocrinol Metab"},{"key":"185_CR23","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.febslet.2008.04.038","volume":"582","author":"P Arner","year":"2008","unstructured":"Arner P, Pettersson A, Mitchell PJ, Dunbar JD, Kharitonenkov A, Ryd\u00e9n M (2008) FGF21 attenuates lipolysis in human adipocytes\u2014a possible link to improved insulin sensitivity. FEBS Lett 582:1725\u20131730","journal-title":"FEBS Lett"},{"key":"185_CR24","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1016\/j.jacc.2013.11.004","volume":"63","author":"MD Jensen","year":"2014","unstructured":"Jensen MD, Ryan DH, Apovian CM et al (2014) AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 63:2985\u20133023","journal-title":"J Am Coll Cardiol"},{"key":"185_CR25","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1475-2840-12-124","volume":"12","author":"Y Shen","year":"2013","unstructured":"Shen Y, Ma X, Zhou J et al (2013) Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovasc Diabetol 12:124","journal-title":"Cardiovasc Diabetol"},{"key":"185_CR26","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1161\/ATVBAHA.113.301599","volume":"33","author":"WS Chow","year":"2013","unstructured":"Chow WS, Xu A, Woo YC et al (2013) Independent of established cardiovascular risk factors serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol 33:2454\u20132459","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"185_CR27","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1038\/sj.ijo.0803732","volume":"31","author":"S Tonstad","year":"2007","unstructured":"Tonstad S (2007) Identifying obese women most at risk from cardiovascular disease. Int J Obes (Lond) 31:S19\u2013S25","journal-title":"Int J Obes (Lond)"},{"key":"185_CR28","unstructured":"Krintus M, Kozinski M, Kubica J, Sypniewska G (2014) Critical appraisal of inflammatory markers in cardiovascular risk stratification. Crit Rev Clin Lab Sci 11:1\u201317 [Epub ahead of print]"},{"key":"185_CR29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.diabres.2011.02.034","volume":"93","author":"X Li","year":"2011","unstructured":"Li X, Fan X, Ren F et al (2011) Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently. Diabetes Res Clin Pract 93:10\u201316","journal-title":"Diabetes Res Clin Pract"},{"key":"185_CR30","doi-asserted-by":"crossref","first-page":"e87102","DOI":"10.1371\/journal.pone.0087102","volume":"9","author":"V Patel","year":"2014","unstructured":"Patel V, Adya R, Chen J et al (2014) Novel insights into the cardio-protective effects of FGF21 in lean and obese rat hearts. PLoS One 9:e87102","journal-title":"PLoS One"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-014-0185-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-014-0185-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-014-0185-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T23:03:37Z","timestamp":1559516617000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-014-0185-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,14]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["185"],"URL":"https:\/\/doi.org\/10.1007\/s40618-014-0185-3","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,14]]}}}